UCB stock heads into the open after a muted Brussels gain

At the close on September 11, 2026, UCB stock in Brussels inched higher, with a modest percent move and limited breadth across the local market. A recent FDA breakthrough therapy designation for Cimzia frames the backdrop as investors head into today’s session.

UCB stock closed at EUR 112.40 on Euronext Brussels on September 11, 2026, up 0.4% from the prior session.

September 11, 2026 in numbers

UCB SA (ISIN BE0003739530) saw a relatively tight trading range on Euronext Brussels on September 11, 2026, with an intraday low near EUR 111 and a high around EUR 113, before settling at EUR 112.40.

According to local market coverage by MarketScreener Nederland, the Brussels market on September 11, 2026 showed only a few gainers, and UCB benefited from positive sentiment around its rheumatoid arthritis treatment Cimzia after the US Food and Drug Administration granted the drug breakthrough therapy status.

Today’s drivers and calendar

As investors look at UCB today, the recent breakthrough therapy designation for Cimzia by the FDA, highlighted in the same MarketScreener Nederland report, remains a key fundamental backdrop, underscoring regulatory momentum for the company’s immunology portfolio.